Journal
EXPERIMENTAL AND MOLECULAR MEDICINE
Volume 44, Issue 5, Pages 311-318Publisher
KOREAN SOC MED BIOCHEMISTRY MOLECULAR BIOLOGY
DOI: 10.3858/emm.2012.44.5.035
Keywords
atherosclerosis; cilostazol; cytokines; disease models, animal; Ginkgo biloba; inflammation; macrophages; reactive oxygen species
Funding
- Ministry of Health Welfare, Korea [A090264]
- Korea Health Promotion Institute [A090264] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
In this study, the synergistic effect of 6-[4-(1-cyclohexyl-1 H-tetrazol-5-yl) butoxy]-3,4-dihydro-2(1H)-quinolinone (cilostazol) and Ginkgo biloba extract (GbE) was examined in apolipoprotein E (ApoE) null mice. Co-treatment with GbE and cilostazol synergistically decreased reactive oxygen species (ROS) production in ApoE null mice fed a high-fat diet. Co-treatment resulted in a significantly decreased atherosclerotic lesion area compared to untreated ApoE mice. The inflammatory cytokines and adhesion molecules such as monocyte chemoattractant-1 (MCP-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), and VCAM-1 which can initiate atherosclerosis were significantly reduced by the co-treatment of cilostazol with GbE. Further, the infiltration of macrophages into the intima was decreased by co-treatment. These results suggest that co-treatment of GbE with cilostazol has a more potent anti-atherosclerotic effect than treatment with cilostazol alone in hyperlipidemic ApoE null mice and could be a valuable therapeutic strategy for the treatment of atherosclerosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available